Upgrade Now

First Commercial Delivery to Cirtec Medical

By Sharecast

Date: Tuesday 10 Mar 2026







RNS Number : 9246V
Ilika plc
10 March 2026
 




 


 


 


10 March 2026


Ilika plc


('Ilika,' the 'Company,' or the 'Group')


 


Ilika Announces Completion of First Commercial Delivery to Cirtec Medical


 


Electrode delivery signals further commercial progress


 


Ilika (AIM: IKA), the UK pioneer in solid state battery technology, announces it has successfully delivered its initial batch of commercial grade StereaxÒ electrode to Cirtec Medical (Cirtec) for Stereax M300 production.


 


In January 2026, Ilika that Cirtec had initiated the commercial electrode supply arrangement with Ilika to support product manufacturing. Ilika has now fulfilled the initial order, its first revenue-generating order from Cirtec.


 


The electrodes will be used in Stereax M300 batteries for validation and customer sampling across a wide range of active implantable medical device (AIMD) applications, including powering implanted sensors, neurostimulators, orthopaedic implants, orthodontic wearables and ophthalmology devices.


 


Shawn Martin, Vice President at Cirtec Medical, said: "Our close technical cooperation with Ilika has developed into an effective operational partnership, ensuring our customers will receive the highest quality product for integration into their devices. "


 


Graeme Purdy, CEO of Ilika, said: "This milestone demonstrates that Ilika's facility in the UK can deliver commercial-grade electrodes to support Cirtec's M300 manufacturing activities. We look forward to ramping our supply activities to meet customer demand."


 


ENDS--


 


Enquiries:


 


























Ilika Plc
Graeme Purdy, Chief Executive


Jason Stewart, Chief Financial Officer


 



www.ilika.com


Via FTI Consulting



 






Cavendish Capital Markets Limited (Nomad and Broker)
Peter Lynch


Neil McDonald


 





+44 (0)131 220 9772


+44 (0)131 220 9771



 






FTI Consulting (Comms Advisors)


Ben Brewerton


Elizabeth Adams


Dwight Burden



ilika@fticonsulting.com



 


About Ilika plc


 


Ilika is a global expert in the development of solid-state battery technology for electric vehicles, medical devices and consumer appliances. The Company's pioneering next-generation technologies aim to provide scalable, affordable alternatives to conventional batteries, to industries which need to incorporate a smaller, lighter, and safer power source in their products.


 


The Company has two product lines. Its Stereax batteries are designed for powering miniature medical implants, industrial wireless sensors and Internet of Things (IoT) applications and the Goliath large format batteries are designed for EV cars and cordless appliances.


 


Through its licensing business model, Ilika supplies its IP portfolio to both OEMs and manufacturing partners in exchange for a license fee and future royalties.


 


About Cirtec Medical‍


 


Cirtec Medical is a global leader in design, development, and manufacturing of complex Class II and III medical devices, specializing inactive implant systems, interventional devices, precision components, and thin film and microelectronics. Since 1987, Cirtec Medical has built extensive in-house capabilities that enable the company to serve as a single-source partner and collaborate with customers to transform their technology into innovative medical devices across a wide array of therapies, including cardiology, neurology, orthopedics and other minimally invasive device applications. Cirtec Medical's deep expertise in precision component design and manufacturing supports every stage of the product lifecycle, ensuring uncompromising quality and performance. With 11 global facilities and a vertically integrated approach, Cirtec Medical aims to expedite time to market, reduce risk, and accelerate revenue generation for our partners. Learn more at CirtecMed.com.


 


 






This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCAKCBQABKDDNK

..

Email this article to a friend

or share it with one of these popular networks:


Top of Page